Fate Therapeutics, Inc. (FATE)

33.83
0.41 1.23
NASDAQ
Prev Close 33.42
Open 33.57
Day Low/High 33.20 / 34.65
52 Wk Low/High 12.59 / 38.52
Volume 499.15K
Exchange NASDAQ
Shares Outstanding 83.87B
Market Cap 2.75B
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Upgrades, Downgrades, New Research

Before I jump on the radio, here's a quick list of upgrades, downgrades and new research coverage coming out of Wall Street this morning... - Hilltop Holdings upgraded to Overweight from Neutral at Piper Jaffray - Trex upgraded to Buy from Hold at S...

Traders Are Still Finding Plenty of Stocks That They Want to Buy

Traders Are Still Finding Plenty of Stocks That They Want to Buy

Sentiment is very positive, regardless of what the indices may say.

Biotech Sector Steps Up to Provide Some Strong Action for Traders

Biotech Sector Steps Up to Provide Some Strong Action for Traders

The S&P 500 has shown the same pattern for three consecutive days.

Surveying the M&A Landscape in Biotech

Surveying the M&A Landscape in Biotech

Who might be in play in the quarters ahead?

The Setup Is Good for a Bounce, but it Hasn't Happened Yet

The Setup Is Good for a Bounce, but it Hasn't Happened Yet

Some small names are interesting, but more-aggressive position trades are not developing right now.

3 Small Biotechs With Insider Buying

3 Small Biotechs With Insider Buying

Insiders have an edge in this complex sector, so it's worth checking them out.

On the Hunt for Holiday Movers

On the Hunt for Holiday Movers

I'm still bullish, but I'm looking over my shoulder to see if there are some bears sneaking up.

Rotation Is the Name of the Game

Rotation Is the Name of the Game

Traders are also looking for smaller-caps that can move big around the holiday.

Shark Bites: These Steel Names Are Looking Strong

Shark Bites: These Steel Names Are Looking Strong

A few plays on this holiday trading.

Pluristem, Capricor Lead Regenerative Space Says Raymond James Analyst

Pluristem, Capricor Lead Regenerative Space Says Raymond James Analyst

Fate Therapeutics (FATE) is developing several small molecules which modulate umbilical cord stem cells.

Prandial Ponderings

Here are a few thoughts as we approch the lunch hour. By Bret Jensen Markets are slightly down across all the major indices as we approach the noon hour.  A few random thoughts: It is hard to see Barney Frank on CNBC saying with a straight face that...

BioTech IPOs With Big Partners

BioTech IPOs With Big Partners

These biotech IPOs all have collaborations with big name companies says Equities.com Francis Gaskins.